Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia.
about
Dissociation of the role of the prelimbic cortex in interval timing and resource allocation: beneficial effect of norepinephrine and dopamine reuptake inhibitor nomifensine on anxiety-inducing distractionSelective noradrenaline reuptake inhibitors for schizophreniaNoradrenergic Modulation of Cognition in Health and Disease.Persistent gating deficit and increased sensitivity to NMDA receptor antagonism after puberty in a new mouse model of the human 22q11.2 microdeletion syndrome: a study in male mice.Effects of caffeine or RX821002 in rats with a neonatal ventral hippocampal lesionMethylphenidate treatment in adolescent rats with an attention deficit/hyperactivity disorder phenotype: cocaine addiction vulnerability and dopamine transporter function.Dopamine, Noradrenaline and Differences in Sexual Behavior between Roman High and Low Avoidance Male Rats: A Microdialysis Study in the Medial Prefrontal Cortex.Pre-gestational stress alters stress-response of pubertal offspring rat in sexually dimorphic and hemispherically asymmetric manner.Clozapine reconstructed: Haloperidol's ability to reduce alcohol intake in the Syrian golden hamster can be enhanced through noradrenergic modulation by desipramine and idazoxanSpecificity and impact of adrenergic projections to the midbrain dopamine system.Catecholamine/Serotonin interactions: systems thinking for brain function and diseasePolyunsaturated fatty acid associations with dopaminergic indices in major depressive disorder.α2-Adrenoceptors are targets for antipsychotic drugs.Psychotic Symptoms Associated with the use of Dopaminergic Drugs, in Patients with Cocaine Dependence or AbuseSleep-related eating disorder associated with mirtazapine.The dopamine beta-hydroxylase inhibitor nepicastat increases dopamine release and potentiates psychostimulant-induced dopamine release in the prefrontal cortex.Nicotine and clozapine cross-prime the locus coeruleus noradrenergic system to induce long-lasting potentiation in the rat hippocampus.Presynaptic regulation of extracellular dopamine levels in the medial prefrontal cortex and striatum during tyrosine depletion.Blockade of α2-adrenergic receptors in prelimbic cortex: impact on cocaine self-administration in adult spontaneously hypertensive rats following adolescent atomoxetine treatment.The selective noradrenergic reuptake inhibitor reboxetine restores spatial learning deficits, biochemical changes, and hippocampal synaptic plasticity in an animal model of depression.Noradrenergic signaling in the VTA modulates cocaine craving.Involvement of 5-HT2A receptor and α2-adrenoceptor blockade in the asenapine-induced elevation of prefrontal cortical monoamine outflow.L-Tyrosine availability affects basal and stimulated catecholamine indices in prefrontal cortex and striatum of the rat.
P2860
Q21129338-FE787DC9-F802-4189-9EDE-666A24AE629DQ24197825-AEA44493-72B2-4C59-83EC-5AB222BC4A12Q30354689-94DD7C49-20C4-4318-823B-EEF01720F9F0Q30359319-7B0DF3DB-0825-43D5-9A54-D38683AFD88DQ30443847-FF27FD63-DABB-4CAA-A8C6-9DC212CCBEABQ30498578-08AA27C3-413B-4E59-AE7D-CD4E8C61F6AEQ33770221-304B4134-27DD-47A7-BD85-92141365EEC8Q34800208-C31BBF42-62C0-4C6B-9DD9-E56600B679A6Q35690285-D6C1BB60-F512-4F60-BD29-C136DC69CE9AQ36932568-B760EBCA-FD62-48E1-A551-954F83BBD213Q37518766-59796651-EACE-47D0-9657-718D84A34AE2Q37640767-D6A24DE7-A063-4E87-9237-5DDAAE73B31EQ38184439-F55762E5-10AB-4B15-8C2B-7E238C99B3A8Q38786578-92F989AE-B6AD-43F3-BD5C-8FAEC97C7976Q43134202-4DFE5390-CDA4-4050-8036-D2A72E6F52F9Q48101589-DAF62657-D92E-41DB-A3FF-48AF651052BCQ48114843-714ADDDF-4B4E-42C3-97C2-CCF06487C5D6Q48181816-48076ABF-50E2-42FB-B290-B730C0645ABCQ48186009-F49DF74A-D63B-469A-97EF-1BCA76A9C69EQ48228347-E0D3340E-0684-4A05-ADBC-05E115D86408Q48246919-7558DDFF-4893-407A-958C-347BFDE87CB3Q48643283-56011892-69E8-4CCB-A596-4301DA149773Q52092911-D9E2F3D9-24FD-45AA-B977-3DE57C1DA631
P2860
Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Selective enhancement of mesoc ...... pportunities in schizophrenia.
@en
Selective enhancement of mesoc ...... pportunities in schizophrenia.
@nl
type
label
Selective enhancement of mesoc ...... pportunities in schizophrenia.
@en
Selective enhancement of mesoc ...... pportunities in schizophrenia.
@nl
prefLabel
Selective enhancement of mesoc ...... pportunities in schizophrenia.
@en
Selective enhancement of mesoc ...... pportunities in schizophrenia.
@nl
P1476
Selective enhancement of mesoc ...... opportunities in schizophrenia
@en
P2093
Francesc Artigas
P356
10.1017/S1461145710000908
P577
2010-08-12T00:00:00Z